Monitor for the FDA's formal decision in May 2026, which will determine the regulatory pathway and potential U.S. approval timeline for LYTENAVA™. Absent approval, the company may face delays in U.S. commercialization and revenue generation.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $0.2900entry
- T+1 · 7mo ago −1.03%α −0.64% · $0.2870
- T+5 · 7mo ago −10.31%α −10.37% · $0.2601
- T+20 · 6mo ago −21.38%α −24.54% · $0.2280
- T+60 · 4mo ago +379.31%α +374.53% · $1.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA to appeal a Complete Response Letter (CRL) for its ONS-5010/ LYTENAVA™ biologics license application. A formal decision from the FDA is expected in May 2026.
Key Facts
- Company held an FDR meeting with the FDA on April 21, 2026, to appeal a CRL issued on December 30, 2025, for ONS-5010/ LYTENAVA™.
- The drug is under development for wet AMD and has already received marketing authorization in the EU and UK.
- The company expects a formal decision from the FDA in May 2026.
- No financial figures or material changes to operations were disclosed.
Financial Impact
No immediate financial impact disclosed; outcome depends on FDA's upcoming decision.
Risk Factors
- FDA may uphold the CRL, delaying or blocking U.S. approval.
- Failure to gain U.S. approval could limit commercial potential and impact company valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-046014 |
| Document: tm2612353d1_ex99-1.htm | 0001104659-26-046014 |
| Document: 0001104659-26-046014-index-headers.html | 0001104659-26-046014 |
| Document: 0001104659-26-046014-index.html | 0001104659-26-046014 |
| Document: 0001104659-26-046014.txt | 0001104659-26-046014 |
Track record
37 reports on OTLK
13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers